Sedentary Behavior
Conditions
Interventions
The present study was divided into two groups: Group1 (n=20) aerobic capacity and Group2 (n=20) anaerobic capacity. The individuals in both groups will undergo 3 days of physical tests, 7 days apart,
Sponsors
Laboratório de Fisiologia do Exercício
Universidade Federal de Ouro Preto
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Athletes and practitioners of physical exercise; older than 18 years; involved in their training programs for at least one year; have participated in competition in the last six months at the regional level
Exclusion criteria
Exclusion criteria: Present some type of illness that compromises data collection; individuals with any type of pathology; smokers; make use of medications such as anti-inflammatories and antibiotics and / or others that may compromise research data; as well as supplements that interfere with cardiovascular parameters such as caffeine and guarana
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected Outcome 1: To evaluate the effect of oral formulation of HPß-CD-Angiotensin- (1-7) (3 mg) in mountain bike (MTB) athletes. Expect to find an increase in physical performance through two different protocols: time trial (TT20km) or interval (4 30-second sprints) on a leg cycloergometer. The researchers hypothesize to observe through the protocols: time trial (reduced duration in seconds) or interval (increased power in watts) post intervention with oral supplementation of HPß-CD-Angiotensin- (1-7) (3 mg).;Outcome found 1: For the time trial protocol there was no significant difference between the HPß-CD-Ang-(1-7) condition and the placebo condition in test time (p=0.76). No statistical differences were observed in maximum power between the conditions (HPßCD- placebo = 187.4 ± 21.46 W vs. HPßCD-Ang- (1-7) = 200.4 ± 28.75 W. Mean power was not different between conditions (HPßCD- placebo = 145.2 ± 14.28 W vs. HPßCD-Ang- (1-7) = 157.9 ± 22.19 W. For the variable rotation per minutes (RPM) no difference was observed between conditions (HPßCD- placebo = 95.3 ± 11.51 rpm vs. HPßCD-Ang- (1-7) = 101.4 ± 14.78 rpm. Finally, speed per hour (km/h) showed no differences between conditions (HPßCD- placebo = 25.65 ± 2.88 km/h vs. HPßCD-Ang- (1-7) = 27.9 ± 3.73 km/h. For the repeated sprint protocol for relative maximum power at each stimulus of the test protocol: 1st (7.0 ± 0.6; 7.3 ± 0.7 W), 2nd (6.6 ± 0.8; 6.8 ± 0.8 W), 3rd (6.1 ± 0.8; 6.2 ± 0.7 W) and 4th (5.7 ± 0.8; 5.7 ± 0.9 W) no statistical differences were observed, as well as for relative average power at each stimulus of the test protocol: 1st (5.5 ± 0.6; 5.5 ± 0.7 W), 2nd (5.3 ± 0.7; 5.2 ± 0.5 W), 3rd (4.9 ± 0.4; 4.8 ± 0.6 W) and 4th (4.5 ± 0.8; 4.5 ± 0.6 W); for the fatigue index in each stimulus of the test protocol: 1st (76.5 ± 15.8; 78.5 ± 15.9 %), 2nd (77.4 ± 13.9; 79.3 ± 18.7 %), 3rd (72.0 ± 18.8; 81.0 ± 17.2 %) and 4th (91.6 ± 8.5; 92.0 ± 9.6 %). Furthermore, there was no difference between the mean value | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2: To evaluate the effect of oral formulation of HPß-CD-Angiotensin-(1-7) (3 mg) in mountain bike (MTB) athletes. The researchers hypothesize that improved physical performance will not promote changes in cardiovascular parameters (such as: systolic and diastolic blood pressure and heart rate) in the condition treated with oral HPß-CD-Angiotensin-(1-7) (3 mg) supplementation at rest or at peak physical exertion when compared to the placebo group.;Outcome found 1: Supplementation with HPß-CD-Ang-(1-7) did not promote changes in cardiovascular parameters in subjects undergoing the repeated sprints protocol either at rest or at peak exertion. Participants in the time trial protocol showed a reduction in resting diastolic blood pressure values (p=0.025). However, resting SBP and HR did not differ between conditions. Furthermore, at peak exertion no differences were observed between the conditions for SBP, DBP and HR. | — |
Countries
Brazil
Contacts
Public ContactLenice Becker
Universidade Federal de Ouro Preto
Outcome results
None listed